Merck, Wyeth Weather Stormy Q2 Despite Setbacks; Not All Fare So Well
Pharmaceutical companies had a relatively stable second quarter, despite several high-profile regulatory setbacks and failures during the period
You may also be interested in...
Sanofi-Aventis intends to resubmit its NDA for Zimulti (rimonabant) pending clarification of FDA's questions regarding its obesity claim. The firm announced it was withdrawing the application June 29, roughly two weeks after the agency's Endocrinologic and Metabolic Drugs Advisory Committee unanimously voted against approval of the cannabinoid-1 receptor antagonist for weight loss
Building on the base of its anti-emetic Zofran, GlaxoSmithKline is poised to broaden its leadership in the market for oncology supportive care with near-term offerings for thrombocytopenia and chemotherapy-induced nausea and vomiting
If FDA concurs with the Endocrinologic and Metabolic Drugs Advisory Committee's negative opinion of the pending obesity indication for Zimulti (rimonabant), Sanofi-Aventis may have another attempt at bringing the drug to market for type 2 diabetes